BTIG Reiterates Buy on Guardant Health, Maintains $195 Price Target

Benzinga Newsdesk www.benzinga.com Neutral 89.7%

Neg 0% Neu 89.7% Pos 0%

BTIG analyst Mark Massaro reiterates Guardant Health (NASDAQ:GH) with a Buy and maintains $195 price target.

Comments

No comments yet. Be the first!